Back to articles

Batch-to-batch variability a concern with dry powder inhalers


Results of a pharmacokinetic (PK) study assessing batch-to-batch variability among three different batches of fluticasone/salmeterol (FP/SAL) dry powder inhalers (DPIs) (Advair Diskus 100/50—GlaxoSmithKline) showed that between-batch variability was significant and may be related to the age of the inhaler, with the oldest batch yielding the lowest systemic exposure.

Recent Articles